Clesacostat
Metabolic Dysfunction-Associated Steatohepatitis
Floatz Rating
BB70/100
Confidence
Indicative
Sponsor
Columbia University
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04395950CT.gov Effects of ACC Inhibitor on Lipid and Lipoprotein Metabolism | — | Withdrawn | — | — | — |
NCT04399538CT.gov Study of Pharmacodynamics and Safety of DGAT2i and ACCi Coadministered in Participants With Sponsor-defined Presumed Non Alcoholic Steatohepatitis | — | Completed | — | — | — |
NCT04321031CT.gov Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) | — | Completed | — | — | — |
NCT03248882CT.gov Phase 2a, Dose-ranging Study With PF-05221304 in Nonalcoholic Fatty Liver Disease (NAFLD) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Metabolic Dysfunction-Associated Steatohepatitis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Clesacostat (this asset) | Columbia University | P2 | BB · 70 |
| Resmetirom | City University of New York | P4 | BBB |
| Pentoxifylline | Al-Azhar University | P4 | BBB |
| Pioglitazone | Badr University | P4 | BBB |
| Firsocostat | Gilead Sciences | P2 | BBB |
| Montelukast | Tanta University | P4 | BBB |
| Rosuvastatin | Beni-Suef University | P4 | BBB |
| Alpha Tocopherol | Shanghai Jiao Tong University School of Medicine | P4 | BBB |
| Ezetimibe | University of Palermo | P4 | BBB |
+42 more in the Metabolic Dysfunction-Associated Steatohepatitis cohort
Other indications for Clesacostat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Metabolic Dysfunction-Associated Steatotic Liver Disease | — | P2 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Citation
Floatz Terminal. Clesacostat in Metabolic Dysfunction-Associated Steatohepatitis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 13, 2026. https://terminal.floatz.ai/assets/clesacostat-metabolic-dysfunction-associated-steatohepatitis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →